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ABSTRACT
Antimicrobial metaphylaxis is an 
important tool used for the prevention 
of bovine respiratory disease complex, 
an economically important disease that 
typically affects newly weaned beef calves 
that are marketed and transported a dis-
tance from their origin. An experiment 
was conducted to determine the effects 
of administering 2 different metaphy-
lactic products [tulathromycin (TULA) 
and gamithromycin (GAMI)] on differ-
ences on core body temperature, health, 
and performance on 284 highly stressed 
stocker calves. Calves were procured and 
delivered (transient time = 13.5 h aver-
age) from a southeastern United States 
order buyer in 3 truckload lots during 
a 6-d period in October 2011. The core 
body temperatures in nonmorbid calves in 
the TULA calves were greater compared 
with the GAMI calves the first 2 h after 
administration and at multiple time 
points on d 4 through 6 of the experi-
ment (P < 0.05). Calves receiving TULA 
experienced less morbidity (P < 0.01) 
and less chronicity (P < 0.05) when 
compared with GAMI calves. Calves in 
the TULA group had greater ADG (P 
< 0.001) from arrival to d 45 compared 
with calves injected with GAMI. This 
experiment indicated that metaphylactic 
products may affect core body tempera-
ture differently, which may be an impor-
tant consideration when managing the 
health of high-risk calves. Moreover, both 
health and performance differences may 
exist among calves administered different 
metaphylactic products. Therefore, prod-
uct selection is an important decision 
when managing high-risk calves.
Key words: beef calf, metaphylaxis, 
core body temperature, health, perfor-
mance
INTRODUCTION
Bovine respiratory disease com-
plex (BRDC) remains an important 
disease in weaned beef calves (Smith, 
1998; NAHMS, 2011c). Multiple 
management practices including 
nutrition, environment, and im-
munization are used to help control 
this disease process (Snowder et al., 
2006). In addition, metaphylaxis, the 
mass administration of antimicrobial 
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products to animals upon arrival at 
stocker and feedlot operations, is 
sometimes used for control of BRDC 
in high-risk cattle, and approximately 
42% of all incoming cattle in feedlots 
with a capacity of less than 1,000 
head and 26.0% of all incoming cattle 
in feedlots with a capacity of 1,000 or 
more head receive an antimicrobial 
injection upon initial processing in 
feedyards (NAHMS, 2011a,b).
The objective of this research was 
to determine whether crossbred beef 
heifer calves administered 2 differ-
ent antibiotics commonly used for 
metaphylaxis, tulathromycin (TULA, 
Draxxin, Pfizer Animal Health, 
New York, NY) and gamithromy-
cin (GAMI, Zactran, Merial Ani-
mal Health, Duluth, GA), differed 
in core body temperature, health, 
and performance. The metaphylaxis 
products were chosen on the basis 
of their recent introduction into the 
animal health market at the time of 
the experiment. It was hypothesized 
that core body temperature may be 
affected by different metaphylactic 
products, and these differences may 
be important considerations when 
diagnosing BRDC. It was also hy-
pothesized that differences may exist 
concerning health and performance in 
calves administered different antibiot-
ics commonly used for metaphylaxis.
MATERIALS AND METHODS
Animals
This experimental protocol was 
approved by the Kansas State Univer-
sity Animal Care and Use Committee, 
Protocol #2910. Crossbred beef heifer 
calves (n = 284; BW = 229 ± 21.9 
kg) were procured through a live-
stock order buyer at various auction 
markets in Alabama and Tennessee 
in October 2011 and transported to 
Dickinson, Tennessee. All cattle were 
then transported, within one day after 
arrival from the Tennessee facility, 
to the Kansas State University Beef 
Stocker Unit (KSBSU), Manhattan, 
Kansas. Before being transported to 
Kansas, all calves were provided ad 
libitum access to long-stem grass hay 
and water. The approximate tran-
sit time from the order buyer barn 
departure to arrival at KSBSU for 
all truckloads was 13 to 14 h. Cattle 
were mixed continental breeds ranging 
in hide colors from yellow to black. 
Three truckloads containing approxi-
mately 90 calves per load arrived at 
the study facility over a 6-d period. 
Arrival dates were October 19, 21, 
and 26, respectively. Calves from each 
truckload were housed within a sepa-
rate string of pens (8 pens per load; 4 
pens per treatment).
Housing and Environment
Calves were housed in 24 identi-
cal pens measuring 9.1 m by 15.2 m. 
Each pen was soil surfaced with a 
concrete fence line feed bunk measur-
ing 9.1 m long, which also included a 
3.6-m concrete apron. No shade was 
present. Average weekly precipitation, 
in centimeters, measured within 1.6 
km of the research facility was as fol-
lows: 0.00, 0.03, 0.53, 0.00, 0.10, 0.28, 
and 0.00 cm for wk 1 to 7, respec-
tively (Weather Source LLC, 2015). 
Maximum daily temperatures, also 
measured 1.6 km from the facility, 
during the study were as follows: 12.2, 
13.9, 22.8, 21.1, 26.7, 28.9, and 26.1°C 
for d 1 to 7, respectively (Weather 
Source LLC, 2015).
Experimental Design
Upon arrival at the KSBSU, calves 
were weighed individually and admin-
istered a visual “dangle”-style ear tag. 
Each calf was assigned to a pen using 
a commercial random number genera-
tor program (Excel, Microsoft Cor-
poration, Redmond, WA). Pens were 
then balanced for arrival weight. A 
coin flip at every other pen was used 
to allocate the treatment for that pen 
with the subsequent pen receiving 
the alternative treatment allocation. 
Therefore, 4 pens within each truck-
load were assigned to each treatment, 
resulting in 12 pens assigned to each 
treatment. All 8 pens within the third 
truckload were selected to participate 
in the core body temperature por-
tion of the study. The selection of this 
subgroup of pens was based on conve-
nience and proximity to the working 
facility.
Treatment Administration
The day after arrival (d 1), calves 
within each load were administered 
their assigned metaphylactic anti-
microbial product. Calves assigned 
to TULA received tulathromycin 
(Draxxin; Pfizer) at 2.5 mg/kg of 
BW and calves assigned to GAMI 
received gamithromycin (Zactran; Me-
rial Limited, Duluth, GA) at 6.0 mg/
kg of BW subcutaneously in the left 
cervical area, cranial to the scapula, 
ventral to the nuchal ligament, and 
dorsal to the vertebrae according to 
beef quality assurance guidelines (Beef 
Quality Assurance, 2016). Treat-
ments were administered to all calves 
by the same individual according to 
labeled instructions. All calves at 
the time of treatment administration 
also received a modified-live vaccine 
containing infectious bovine rhino-
tracheitis virus, bovine viral diarrhea 
virus, bovine respiratory syncytial 
virus, and parainfluenza virus (Bovi-
Shield Gold 5; Pfizer) subcutaneously 
in the right cervical area, as described 
above, and a parasiticide (Ivomec 
Pour-On; Merial Limited) according 
to label instructions. Additionally, 
each calf was administered, subcuta-
neously in the right cervical area, as 
described above, a toxoid containing 
Clostridium chauvoei, Clostridium 
perfringens, Clostridium septicum, 
Clostridium novyi, and Clostridium 
sordellii (UltraChoice 7; Pfizer) the 
day after arrival and on d 28 per 
labeled instructions. At the time of 
antibiotic administration, an ear bi-
opsy was collected from the left ear of 
each calf and submitted to the Kansas 
State Veterinary Diagnostic Labora-
tory for bovine viral diarrhea virus 
PCR analysis.
Core Body Temperature 
Assessment
Calves in 8 pens and from within 
one truckload (third arrival load) 
were monitored for core body tem-
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perature via vaginal temperature over 
the first 7 study days after antibiotic 
administration. Vaginal temperature 
was captured using stainless steel 
temperature loggers (U12–015 HOBO; 
Onset, Bourne, MA) attached to non-
hormonally impregnated controlled 
internal releasing devices (CIDR; 
Pfizer). The intravaginal devices were 
inserted in each calf when allocated 
treatments were administered on d 1. 
Vaginal temperature was logged every 
10 min, and data were averaged over 
1-h periods. To allow the tempera-
ture device to come to equilibrium, 
the first 20 min of recordings after 
initial insertion were not used in the 
analysis. The intravaginal devices 
were removed on d 8. For the core 
body temperature portion of the 
study, temperature values were aver-
aged across pens, and only data from 
nonmorbid calves were analyzed and 
included 43 TULA and 44 GAMI 
calves. Data from 2 calves in TULA 
and 3 calves in GAMI were excluded 
from the analysis because the data 
logger was not retained for the entire 
study period. Data from 2 additional 
calves in GAMI were removed from 
the study because the data logger 
stopped recording during the study. 
There was approximately a 2.1-h time 
span from the insertion of the vaginal 
device in the first calf to the insertion 
of the vaginal device in the last calf 
within this subset.
Health Monitoring
Calves were observed by KSBSU 
animal caregivers twice a day to 
determine health status. The care 
givers were blinded to the treatment 
allocation for each pen. A 5-d post-
metaphylactic antimicrobial treatment 
moratorium was used in this experi-
ment. At the end of the moratorium, a 
clinical illness scoring system of 1 to 4 
(1, normal; 2, mild depression, gaunt; 
3, severe depression, labored breath-
ing; and 4, moribund, near death, 
little response to human approach) 
was used to determine health status. 
Calves with a score greater than 1 
were taken to the working facility 
for examination. Those calves with a 
clinical illness score >1 and a rectal 
temperature ≥40°C taken during the 
examination and not presenting signs 
indicative of nonrespiratory disease 
were determined to be experiencing 
BRDC. Bovine respiratory disease 
complex calves were administered 
antibiotics according to the KSBSU 
standard operating procedure. The 
treatment regimen for BRDC was 
first illness, florfenicol (Nuflor; Merck 
Animal Health, Madison, NJ) at 40 
mg/kg of BW; second illness, enro-
floxacin (Baytril; Bayer Health Care 
LLC, Animal Health, Pittsburgh, 
PA) at 10 mg/kg of BW; third ill-
ness, oxytetracycline (Biomycin 200; 
Boehringer Ingelheim Vetmedica Inc., 
St. Joseph, MO) at 4 mg/kg of BW. 
Calves continuing to express a clinical 
illness score >1 and a rectal tempera-
ture ≥40°C on d 3 after first or second 
treatment were administered the 
next scheduled treatment product as 
described above. A hospital pen was 
not used in this study; all calves were 
returned to their original pen after 
physical examination and medication. 
Chronic calves were defined as calves 
experiencing BRDC for the third time. 
These calves were returned to their 
home pen and not administered anti-
microbials again. Investigated health 
outcomes included BRDC morbidity, 
case fatality, chronicity, and mortality.
Performance Assessment
All calves were individually weighed, 
using a livestock scale (Avery Weigh-
Tronix, Model 640, Fairmont, MN), 
immediately upon arrival (d 0), at 
revaccination (d 28), and at study 
completion (approximately d 45). Av-
erage daily gain was calculated from 
individual weights taken immediately 
upon arrival to the KSBSU to d 28 
and from arrival to study comple-
tion for all calves. All BW measures 
were collected before feeding at ap-
proximately 0800 h on each respective 
weigh day. Dry matter intake and 
G:F were calculated for each pen of 
heifers and each period (d 0 to 28, 0 
to 56). Average daily gain for all time 
periods was calculated with mortali-
ties removed.
Feeding Program
For the first 2 d upon arrival calves 
were given ad libitum access to water 
and to medium quality prairie hay 
(7.0% CP, 0.44 Mcal/kg NEg; Table 
1). From d 3 to study completion, 
the calves were fed a TMR consisting 
of mixed grass hay, alfalfa hay, dry 
rolled corn, wet corn gluten feed, and 
a commercial pellet (Cargill Animal 
Nutrition, Minneapolis, MN; Table 
1). Feed bunks were scored twice 
daily, and subsequent feed amounts 
delivered were based on the amount 
of feed not consumed at the previous 
feeding.
Statistical Analysis
Data were statistically analyzed 
with pen as the experimental unit 
using a commercial software program 
(STATA v. 12.0). The experimental 
design was a completely random-
ized, blocked by truck load, blinded 
clinical study. Generalized estimating 
equations accounting for repeated 
measures and pen within truckload as 
random effects were used to analyze 
core body temperature data. The 
fixed effects were treatment, hour, 
and day; the correlation structure was 
AR(1) (Dohoo et al., 2003). Logistic 
regression models were used to ana-
lyze health outcome data. Treatment 
was the fixed effect, and pen within 
truckload were included as random 
effects to account for a lack of inde-
pendence among calves. Generalized 
mixed models were used to investigate 
associations between treatment and 
ADG. Random effects in this model 
included pen within truckload, and 
treatment was the fixed effect. A 
2-sided P-value of 0.05 was considered 
significant for all models.
RESULTS AND DISCUSSION
Core Body Temperature
In the present study, continuous 
vaginal temperatures were captured in 
one truckload of calves (93 head) us-
ing data loggers. Multiple studies have 
concluded that vaginal temperature is 
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an acceptable method to monitor core 
body temperature in cattle (Davis et 
al., 2003; Vickers et al., 2010; Burdick 
et al., 2012). Rectal temperature, not 
vaginal temperature, is commonly 
used to measure core body tempera-
ture in cattle; therefore, for vaginal 
temperatures to be of value, their 
correlation with rectal temperature is 
important. The correlation between 
rectal and vaginal temperature was 
determined to be 0.97 (P < 0.001) 
in a study simultaneously measuring 
vaginal and rectal temperatures in 
beef heifers (Burdick et al., 2012).
A diurnal core body temperature 
pattern was observed through the first 
7 study days (Figure 1). This diurnal 
pattern was also reported in other 
studies and is considered to be normal 
bovine reactions to ambient tempera-
ture changes (Lefcourt and Adams, 
1996, 1998; Davis et al., 2003). Mean 
core body temperature was greater for 
TULA on h 1 and 2 after metaphy-
lactic treatment (Figure 1). Although 
manufacturers of both antimicrobial 
products used in this study report 
transient local tissue reaction may oc-
cur immediately following administra-
tion, it is possible that one product, 
possibly either through the active 
ingredient or proprietary carrier, 
produces a more intense reaction as 
measured by core body temperature 
(Merial Limited, 2012; Pfizer Inc., 
2012). Inflammatory response differ-
ences associated with product dosage 
have been reported; one study report-
ed greater inflammatory response in 
a greater dose vaccine compared with 
a lesser dose vaccine (Stokka et al., 
1994). This is in contrast to the pres-
ent study’s findings, which suggest 
the lesser dose product (TULA) may 
have produced a greater inflamma-
tory response than GAMI as mea-
sured by core body temperature. The 
difference in study findings may be 
explained by the product differences 
(vaccines compared with antimicrobi-
als) within the 2 studies. Addition-
ally, TULA core body temperatures 
were greater at multiple time points 
including h 84, 85, 106 to 113, 115 
to 117, 119 to 120, and 132 to 140 
after insertion (Figure 1). These time 
points coincided with the afternoon 
time periods of study d 4, 5, and 6. 
Mean ambient temperature during the 
first 7 study days was 12.5°C (range: 
5.6–23.9°C). It is interesting that 
mean core body temperatures peaked 
for one or both treatment groups at 
or above 40.0°C on days when the 
ambient temperature peak ranged 
from 12.2 to 26.1°C (Figure 1). The 
40.0°C level is important because it is 
a value used by many cattle-feeding 
units, including the KSBSU, to clas-
sify calves as BRDC cases. Addition-
ally, the ambient temperatures during 
these time periods are relatively close 
to the reported bovine thermoneutral 
threshold of 15 to 25°C (NRC, 1984). 
The present study indicates that even 
on days not considered to be above 
the bovine thermoneutral zone, core 
body temperatures above established 
disease-indicating thresholds can oc-
cur in some calves. The results from 
the present study may suggest that 
using continuous core body tempera-
ture as a criterion for BRDC case 
definition may have reduced specific-
ity depending on what time of day the 
temperatures are collected. Some re-
searchers have suggested that BRDC 
clinical illness recognition by animal 
caregivers is an insensitive diagnostic 
tool (Bryant et al., 1999; White and 
Renter, 2009). Although only calves 
not classified as BRDC cases during 
Table 1. Composition (% of DM) of growing diets fed during an 
experiment comparing 2 metaphylaxis treatments in crossbred beef 
heifer calves
Item
% of DM,  
unless shown1
Ingredient composition, % of DM
 Dry-rolled corn 28.6
 Wet corn gluten feed 30.0
 Alfalfa hay 17.5
 Prairie hay 17.5
 Supplement2 6.4
 Corn gluten feed 1.8
  Wheat middlings 3.1
  Salt 0.38
  Limestone 0.82
  Potassium chloride 0.02
  Magnesium oxide 0.01
  Beef vitamin premix2 0.001
  Ruminant trace mineral2 0.001
  Molasses 0.19
  Rumensin3 0.014
Nutrient composition, analyzed4  
 DM 79.3
 CP 13.2
 Starch 26.5
 Ether extract 2.7
 ADF 24.7
 Ca 0.67
 P 0.45
 Calculated NEg, Mcal/kg 1.20
1Provided 0.5 mg/d of melengestrol acetate (Pfizer Animal Health, New York, NY), 
which was supplemented through a commercially prepared mineral supplement 
(Cargill Animal Nutrition, Minneapolis, MN).
2Manufactured by Cargill Animal Nutrition (Minneapolis, MN).
3Diet provided 31 mg/kg of monensin (Elanco Animal Health, Indianapolis, IN).
4Analyses conducted at SDK Laboratories (Hutchinson, KS).
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the entire study period were included 
in the core body temperature portion 
of the present study, it is possible that 
some calves in the core body tem-
perature portion of the present study 
may have been experiencing subclini-
cal respiratory disease on those days 
when group mean temperatures were 
elevated. Because other diagnostic 
tests, including at-slaughter lung scor-
ing, were not used in this study, it is 
not possible to determine the level of 
subclinical BRDC occurring in this 
subset.
Some studies have investigated 
differences in core body tempera-
ture between classes of antimicrobi-
als (Fajt et al., 2004). Because both 
of the antimicrobials in the present 
study were macrolides, they would be 
expected to have similar antimicrobial 
and immunomodulation properties 
(Ianaro et al., 2000; Woo et al., 2002). 
Some researchers have concluded that 
macrolides can upregulate the innate 
immune response depending on the 
active ingredients and concentra-
tions (Woo et al., 2002). Additionally, 
macrolides have demonstrated im-
mune modifying properties in animal 
respiratory disease, which may be 
important in clinical applications 
(Woo et al., 2002). It is plausible that 
TULA has different immunomodulat-
ing properties compared with GAMI, 
including cytokine upregulation, 
expressed through elevated core body 
temperature; this may have amelio-
rated the effects of BRDC associated 
pathogens (Tizard, 2013). In several 
studies, administering cytokines be-
fore infection with bovine herpes virus 
1 was found to reduce clinical signs 
(Babiuk et al., 1985, 1987, 1991). 
Therefore, it is also possible, although 
only calves not recorded as BRDC 
cases were included in the core body 
temperature study, that TULA calves 
expressed less clinical BRDC because 
of product-associated immunomodula-
tion. The findings presented here sug-
gests that some antimicrobial prod-
ucts may have unmeasured properties 
that may provide additional health 
benefits to calves.
Health
No animals were determined to be 
bovine viral diarrhea virus persis-
tently infected by PCR. Mortality was 
2.1 ± 1.2% (3/141) and 1.4 ± 0.9% 
(2/143) for TULA and GAMI, respec-
tively. Case fatality was 5.0 ± 2.8% 
(3/60) for TULA and 2.4 ± 1.7% 
(2/83) for GAMI. In the multivariable 
model, morbidity was less (P = 0.013) 
for TULA (41.6 ± 4.7%) compared 
with GAMI (58.3 ± 4.7%; Table 2). 
The percentage of chronics was less 
(P = 0.048) for TULA calves (5.7 ± 
1.9%) compared with GAMI calves 
(12.6 ± 2.8%). There was no statis-
tical difference (P > 0.40) between 
TULA and GAMI calves for either 
mortality or case fatality rate. The 
morbidity and mortality results of 
the present study do not agree with a 
metaphylaxis study completed in Italy 
where gamithromycin calves experi-
enced less morbidity and mortality 
compared with tulathromycin calves 
(Sgoifo Rossi et al., 2010). In the 
Italian study very low morbidity (14.6 
and 9.3%) and mortality (0.4 and 
0.6%) was observed in both groups, 
which may explain the different find-
ings between these 2 studies. It is also 
possible that there are geographical 
differences in pathogen susceptibility 
patterns or pharmacogenomic differ-
ences within cattle populations from 
different countries, which may help 
explain the differences in the health 
outcomes between the 2 studies. 
These plausible differences may be 
important to consider when compar-
ing antibiotic effectiveness studies 
across geographical areas and geneti-
cally different animals.
Performance
The ADG from arrival to revaccina-
tion (d 28) for TULA was greater (P 
< 0.001) than GAMI: 1.51 versus 1.27 
kg/d, respectively (Table 3). Over the 
entire study period (45 d), TULA also 
outgained GAMI calves (P < 0.001), 
1.42 and 1.24 kg/d for TULA and 
GAMI, respectively (Table 3). Ad-
ditionally, for calves not designated as 
chronic, the ADG from arrival to d 28 
ADG in calves administered TULA 
was greater (P < 0.001) than GAMI: 
1.55 versus 1.34 kg/d, respectively. 
Additionally, the ADG from arrival 
to d 45 between nonchronic calves 
administered TULA (1.41 kg/d) was 
Figure 1. Model adjusted mean hourly core-temperature patterns for crossbred 
beef heifer calves administered 2 different metaphylactic products. Model contained 
program, hour, day, and interaction terms (program × hour × day) and accounted 
for repeated measurements within calves and random effect of pen within truckload. 
TULA = tulathromycin (2.5 mg/kg); GAMI = gamithromycin (6 mg/kg) *P ≤ 0.05 
for difference in core temperature as measured by vaginal temperature between 2 study 
groups.
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greater (P < 0.001) than GAMI (1.27 
kg/d). Given the TULA calves expe-
rienced less morbidity and chronicity 
than GAMI calves, these findings are 
not surprising and agree with other 
studies showing the negative effects of 
BRDC on calf performance (Gardner 
et al., 1999; Waggoner et al., 2007). 
No statistical differences in DMI or 
G:F between TULA calves and GAMI 
calves were found for time periods 
arrival to d 28 and arrival to d 45 
(Table 3).
IMPLICATIONS
At several time points, calves ad-
ministered tulathromycin or gamithro-
mycin upon arrival, and not experi-
encing BRDC, experienced different 
core body temperatures. This study 
suggests that core body temperature 
may be affected for extended periods 
of time after metaphylactic product 
administration, depending on the 
antimicrobial product. Additionally, 
healthy calves administered either 
metaphylactic product experienced 
peak mean core body temperature 
levels after administration at or above 
values commonly considered to be 
within normal, healthy bovine ranges. 
This finding may suggest that contin-
uous core body temperature measure-
ment may have reduced BRDC diag-
nostic specificity; therefore, calves not 
experiencing BRDC may be falsely 
identified as positive BRDC calves by 
caregivers. Additionally, calves admin-
istered TULA experienced less BRDC 
morbidity and chronicity and greater 
ADG compared with calves adminis-
tered GAMI.
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1Model included pen within truckload as random effect.
2Number experiencing outcome/number at risk.
3TULA = tulathromycin (2.5 mg/kg of BW); GAMI = gamithromycin (6 mg/kg of BW).
Table 3. Model1 adjusted ADG, DMI, G:F, SE, and P-values of health 
outcomes comparing 2 antimicrobial products in crossbred beef heifer 
calves
Time period
Treatment2
SE P-valueTULA GAMI
Arrival weight, kg 229.7 229.8 0.98 0.970
ADG, arrival to d 28, kg/d 1.51 1.27 0.03 <0.001
ADG, arrival to d 45, kg/d 1.42 1.24 0.03 <0.001
DMI, arrival to d 28, kg/d 5.47 5.46 0.09 0.983
DMI, arrival to d 45 kg/d 6.47 6.59 0.08 0.384
G:F, arrival to d 283 0.26 0.25 0.01 0.855
G:F, arrival to d 453 0.21 0.20 0.01 0.945
1Model included pen within truckload as random effect.
2TULA = tulathromycin (2.5 mg/kg of BW); GAMI = gamithromycin (6 mg/kg of BW).
3Calculated from total gain over total DMI.
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